TY - JOUR
T1 - Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer
AU - Berretta, Massimiliano
AU - Lleshi, Arben
AU - Zanet, Ernesto
AU - Bearz, Alessandra
AU - Simonelli, Cecilia
AU - Fisichella, Rossella
AU - Nasti, Guglielmo
AU - Berretta, Salvatore
AU - Tirelli, Umberto
PY - 2008/7
Y1 - 2008/7
N2 - Background: In the era of highly active antiretroviral therapy (HAART), malignancies are the primary cause of increased mortality in patients with human immunodeficiency virus (HIV) infection, hence representing a new challenge for oncologists. To date, there is little evidence in the English literature about chemotherapy treatment in HIV-positive patients with metastatic colorectal cancer. Case Report: We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART. No opportunistic infections and grade 3-4 haematological and non-haematological toxicity were reported. The HIV infection was kept under control during the bevacizumab chemotherapy treatment. Conclusions: This case suggests that, in the HAART era, the best multidisciplinary approaches can be offered to HIV-positive patients with metastatic colorectal cancer, who have a good performance status and a well controlled HIV infection. An HIV infection should not preclude the use of the best available chemotherapy treatment in this particular group of patients, including targeted/biological drugs.
AB - Background: In the era of highly active antiretroviral therapy (HAART), malignancies are the primary cause of increased mortality in patients with human immunodeficiency virus (HIV) infection, hence representing a new challenge for oncologists. To date, there is little evidence in the English literature about chemotherapy treatment in HIV-positive patients with metastatic colorectal cancer. Case Report: We describe the case of an HIV-positive 48-year-old male patient with metastatic colorectal cancer, treated with a bevacizumab, irinotecan, fluorouracil, and leucovorin regimen, with concomitant HAART. No opportunistic infections and grade 3-4 haematological and non-haematological toxicity were reported. The HIV infection was kept under control during the bevacizumab chemotherapy treatment. Conclusions: This case suggests that, in the HAART era, the best multidisciplinary approaches can be offered to HIV-positive patients with metastatic colorectal cancer, who have a good performance status and a well controlled HIV infection. An HIV infection should not preclude the use of the best available chemotherapy treatment in this particular group of patients, including targeted/biological drugs.
KW - Bevacizumab
KW - Chemotherapy
KW - Colorectal cancer
KW - HAART
KW - HIV
UR - http://www.scopus.com/inward/record.url?scp=47049102052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47049102052&partnerID=8YFLogxK
U2 - 10.1159/000132360
DO - 10.1159/000132360
M3 - Article
C2 - 18596388
AN - SCOPUS:47049102052
VL - 31
SP - 394
EP - 397
JO - Onkologie
JF - Onkologie
SN - 0378-584X
IS - 7
ER -